drugset

drugset / Trial / NCT06427395

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

NCT06427395 ↗

Phase 3 Active not recruiting 102 enrolled Zydus Therapeutics Inc.

NaSingle-groupOpen-labelTreatment

Summary

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Timeline

Start: 2024-07-16
Primary completion: 2027-04-18
Completion: 2027-07-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Saroglitazar	Small molecule	1 mg	Oral

Indications